There is one, and it is real. The Food and Drug Administration approved suzetrigine, sold as Journavx, in January 2025 — the first new class of pain medicine cleared in more than two decades. It is not an opioid, it is not a controlled substance, and it is not expected to cause dependence.
Opioids work inside the brain, dulling the response to a signal that has already arrived. Suzetrigine works earlier, blocking a sodium channel in the peripheral nerves so the signal never completes the trip. Staying out of the brain, it does not produce the euphoria that drives addiction.
It is also not stronger. In the two pivotal trials, published in Anesthesiology, patients recovering from abdominal or bunion surgery got more relief than from a placebo, and roughly the same as from hydrocodone with acetaminophen. Not more. What differed was tolerance. In one trial, 20 percent on suzetrigine reported nausea or vomiting, against 33 percent on the opioid.
The label covers short-term pain only, for no more than 14 days. That restriction is not about danger. Side effects were mild, with itching in about 2 percent of patients and muscle spasms, rash, and a rise in one muscle enzyme each near 1 percent, and no serious reactions were tied to the drug. The cap exists because 14 days is the longest anyone has studied it.
Arthritis and chronic back pain are a separate question, still unanswered. A mid-stage trial in nerve-related low back pain barely beat placebo. A late-stage trial in diabetic nerve pain is enrolling 1,100 patients now.
Then there is the price. Without insurance, a 30-tablet supply — about one full course — runs an estimated $475 to $675, and coverage is uneven. A patient whose plan says no is back to the same choices as before.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.
